Group 1 - The company has received the drug registration certificate for Desloratadine Oral Suspension from the National Medical Products Administration, indicating compliance with drug registration requirements [1][4] - The drug is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children aged 2 and above, and chronic idiopathic urticaria in children aged 6 months and above [2][3] - The product is classified as a prescription drug and falls under the category of Class 3 chemical drugs, with a specification of 120ml containing 0.72g of the active ingredient Desloratadine [6][4] Group 2 - The approval of Desloratadine Oral Suspension will help the company expand its product pipeline and enhance its therapeutic area coverage [4] - The company plans to strengthen quality and process control during the product's subsequent mass production and market launch [4] - The drug registration number for Desloratadine is H20255183, and the manufacturing entity is Chongqing Little Sunflower Children's Pharmaceutical Co., Ltd., a subsidiary of the company [6][4]

Group 1 - The core point of the article is that Kew Flower Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its oral suspension of Fexofenadine Hydrochloride [2] Group 2 - The approval of the drug registration indicates a significant milestone for the company in expanding its product portfolio [2] - This development may enhance the company's market position in the pharmaceutical industry, particularly in allergy treatment [2] - The registration could lead to increased revenue opportunities for Kew Flower Pharmaceutical as it introduces the new product to the market [2]

Core Viewpoint - The approval of the oral suspension of Fexofenadine Hydrochloride by the National Medical Products Administration will enhance the company's product pipeline and therapeutic coverage in the allergy treatment sector [1] Group 1 - The company has received a drug registration certificate for Fexofenadine Hydrochloride oral suspension [1] - This product is aimed at the allergy treatment market, indicating a strategic expansion in the company's offerings [1] - The company plans to accelerate the mass production and market launch of this product, facilitating the rapid conversion of research outcomes into marketable products [1]

格隆汇9月1日丨葵花药业(002737.SZ)公布，公司子公司于近日收到国家药品监督管理局下发的关于盐 酸非索非那定口服混悬液获批注册的药品注册证书。盐酸非索非那定口服混悬液应用于抗过敏领域，该 产品的获批将有助于公司拓展产品管线、完善品类布局、提升治疗领域覆盖，公司将加速推进产品的后 续量产上市，实现研发成果快速转化。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its subsidiary's drug, a hydrochloride formulation of fexofenadine oral suspension, which is now registered as a prescription medication [1] Group 1: Drug Approval Details - The drug is classified as a Class 3 chemical drug and is intended for the relief of seasonal allergic rhinitis symptoms in children aged 2 years and older, as well as chronic idiopathic urticaria skin symptoms in children aged 6 months and older [1] - The registered specification of the drug is 120ml containing 0.72g of the active ingredient [1]

Group 1 - The company announced that its subsidiary has received a drug registration certificate from the National Medical Products Administration for the oral suspension of Fexofenadine Hydrochloride [1] - The drug is classified as a Class 3 chemical drug and is a prescription medication [1] - The approved specifications for the drug are 120ml:0.72g, and it is indicated for alleviating symptoms of seasonal allergic rhinitis in children aged 2 years and older, as well as chronic idiopathic urticaria skin symptoms in children aged 6 months and older [1]

Financial Performance - In 2024, the company reported a revenue of 3.377 billion yuan, a year-on-year decrease of 40.76% [2] - The net profit attributable to shareholders was 492 million yuan, down 56.03% year-on-year [2] - The net profit after deducting non-recurring items was 345 million yuan, a decline of 65.65% year-on-year [2] - Basic earnings per share were 0.84 yuan, with a weighted average return on equity of 10.76% [2] Expense Structure - Total operating expenses for 2024 amounted to 955 million yuan, a reduction of 981 million yuan year-on-year, resulting in an expense ratio of 28.28% [5] - Sales expenses significantly decreased by 68.46% due to channel adjustments, while R&D expenses slightly decreased by 3.51% [5] - Financial expenses increased by 27.73% year-on-year [5] Business Segmentation - Revenue from traditional Chinese medicine was 2.463 billion yuan, down 40.55%, accounting for 72.96% of total revenue [5] - The core product, liver-protecting tablets, achieved sales exceeding 1 billion yuan, but respiratory products saw a significant decline in sales due to high base effects and reduced demand [5] - Revenue from chemical drugs was 712 million yuan, a decrease of 47%, representing 21% of total revenue [5] Product Development - The company has over 60 children's products covering cold, digestive, and respiratory fields, with nearly 30 products achieving sales over 10 million yuan [5] - Adult medications focus on cardiovascular and rheumatic diseases, maintaining a leading market share for liver-protecting tablets [5] - Ten chemical drugs and three traditional Chinese medicine products are in the pilot testing stage, with some products already accepted for review [5] R&D Investment - R&D investment for 2024 was 124 million yuan, accounting for 3.68% of revenue, with a continued focus on the "buy, modify, connect, research, and substitute" strategy, particularly in children's and chronic disease medications [5] Dividend Distribution - The company plans to distribute a cash dividend of 5 yuan per 10 shares (including tax) for 2024 [6]